OTCMKTS:TBUFF Tribute Pharmaceuticals Canada (TBUFF) Stock Price, News & Analysis $0.93 -0.02 (-1.83%) (As of 02/4/2016) Add Compare Share Share Today's Range$0.90▼$0.9650-Day Range N/A52-Week Range$0.50▼$1.86Volume50,100 shsAverage Volume71,826 shsMarket Capitalization$105.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Tribute Pharmaceuticals Canada alerts: Email Address Ad Brownstone Research My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. About Tribute Pharmaceuticals Canada Stock (OTCMKTS:TBUFF)Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.Read More TBUFF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TBUFF Stock News HeadlinesSeptember 6, 2024 | reuters.comTIFF 2024: Tragically Hip series honors beloved Canadian bandMay 17, 2024 | finance.yahoo.comValeo Pharma Inc. (VPHIF)September 16, 2024 | Brownstone Research (Ad) My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.May 2, 2023 | yahoo.comWhen her brother died, she wrote a moving tribute on a frisbee. Now, his memory is being shared from one city to the next.April 27, 2023 | finance.yahoo.comMITSUBISHI TANABE PHARMA CANADA RECEIVES ENGAGEMENT LETTER FROM PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSIONMarch 21, 2023 | mirror.co.ukKate Middleton pays tribute to 'incredibly sad' William as they mark St Patrick's DayOctober 16, 2022 | bbc.co.ukQueen Elizabeth II: Boats, tugs and ferries take part in Mersey tributeOctober 4, 2022 | mirror.co.ukLiz Truss pays tribute to Queen in 'passing of second Elizabethan age - speech in fullSeptember 16, 2024 | Brownstone Research (Ad) My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.October 3, 2022 | bbc.co.ukFriends and colleagues pay tribute to Bill TurnbullSeptember 18, 2022 | investing.comTribute Pharmaceuticals Canada Inc (TRX)See More Headlines Receive TBUFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tribute Pharmaceuticals Canada and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2014Today9/16/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:TBUFF CUSIPN/A CIKN/A Webwww.tributepharma.ca Phone+1-905-8761118FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares113,720,000Free FloatN/AMarket Cap$105.76 million OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesArnold Tenney (Age 70)Chairman of the Board Robert Harris (Age 57)President, Chief Executive Officer, Director Scott Langille (Age 56)Chief Financial Officer, Director Janice M. Clarke (Age 52)Vice President - Finance and Administration Steven H. Goldman (Age 57)Independent Director John M. Gregory (Age 60)Independent Director John J. Kime (Age 70)Independent Director Francis Martin Thrasher (Age 61)Independent Director More ExecutivesKey CompetitorsInstil BioNASDAQ:TILGH ResearchNASDAQ:GHRSCryoportNASDAQ:CYRXCanopy GrowthNASDAQ:CGCNorthwest BiotherapeuticsOTCMKTS:NWBOView All Competitors TBUFF Stock Analysis - Frequently Asked Questions How have TBUFF shares performed this year? Tribute Pharmaceuticals Canada's stock was trading at $0.93 at the beginning of the year. Since then, TBUFF stock has increased by 0.0% and is now trading at $0.93. View the best growth stocks for 2024 here. How were Tribute Pharmaceuticals Canada's earnings last quarter? Tribute Pharmaceuticals Canada Inc. (OTCMKTS:TBUFF) posted its quarterly earnings data on Monday, March, 31st. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.01. The company earned $2.90 million during the quarter. How do I buy shares of Tribute Pharmaceuticals Canada? Shares of TBUFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TBUFF) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tribute Pharmaceuticals Canada Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tribute Pharmaceuticals Canada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.